Should You Request Gastric Mucosal Biopsies for Mast Cell Assessment During Your EGD?
Obtaining gastric mucosal biopsies during your EGD to evaluate for mast cell activation disorder is generally not recommended as a routine diagnostic approach, because the diagnostic utility of intestinal mast cell counts remains controversial and poorly standardized. 1
The Preferred Diagnostic Pathway for MCAS
The most recent 2025 AGA guidelines are clear that serum tryptase testing—not tissue biopsies—is the primary diagnostic approach for mast cell activation syndrome (MCAS) 1. Here's the algorithmic approach:
Step 1: Determine If You Meet Clinical Criteria for MCAS Testing
MCAS testing should only be pursued if you have:
- Episodic symptoms affecting 2 or more organ systems (cutaneous, GI, cardiac, respiratory, neuropsychiatric)
- Symptoms such as: flushing, pruritus, urticaria, angioedema, wheezing, tachycardia, abdominal cramping, vomiting, nausea, diarrhea, or neurological complaints
- Not just isolated GI symptoms alone 1
Step 2: The Correct Diagnostic Test is Serum Tryptase
If MCAS is suspected based on the above criteria:
- Obtain baseline serum tryptase level (when you're asymptomatic)
- Obtain serum tryptase 1-4 hours after a symptom flare
- A diagnosis requires: 20% increase above baseline PLUS an absolute increase of 2 ng/mL 1
Step 3: Why Intestinal Biopsies Are Not the Answer
The guidelines explicitly state that "the threshold distinguishing normal from abnormal mast cell counts is debated" in intestinal biopsies 1. While some have proposed counting mast cells per high-power field or using CD-117 immunohistochemical staining in the duodenum or ileum, "consensus for these guidelines, even among allergists, is controversial" 1.
Important Caveats and Pitfalls
Common Pitfall #1: Requesting mast cell biopsies without first establishing clinical suspicion through the symptom criteria above. This leads to overdiagnosis and unnecessary testing.
Common Pitfall #2: Confusing MCAS with systemic mastocytosis (SM). The NCCN guidelines for SM do discuss bone marrow biopsies showing mast cell infiltrates, but this is for a different, clonal disorder requiring bone marrow evaluation—not routine GI biopsies 2, 3.
Common Pitfall #3: Not obtaining the baseline tryptase first. Without a baseline, you cannot interpret a post-flare level appropriately.
What You Should Actually Do
Before your EGD: Discuss with your provider whether you meet clinical criteria for MCAS (multi-system episodic symptoms as described above)
If you do meet criteria: Request a baseline serum tryptase level now (before the procedure), not tissue biopsies during the EGD
If MCAS is ultimately supported by clinical and laboratory findings: You should be referred to an allergy specialist or mast cell disease research center for additional testing (urinary N-methylhistamine, leukotriene E4, 11b-prostaglandin F2) 1
Your EGD should proceed as planned for its original indication, focusing on structural and anatomical evaluation rather than mast cell assessment
The evidence strongly supports that blood tests, not biopsies, are the appropriate first-line diagnostic approach for MCAS, and tissue-based mast cell evaluation remains too controversial and unstandardized to guide clinical decision-making 1.